EyePoint Pharmaceuticals Investor Presentation — August 2020

Document content

August 2020NOT FOR PROMOTIONAL USE

Disclaimers and Notices

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , that involve substantial risks and uncertainties,

including statements regarding INVELTYS® and its commercial progress, the Company's lead product candidate, EYSUVISTM, for the short -term relief of the signs and symptoms of

dry eye disease, including expectations regarding timing of FDA review of the New Drug Application (NDA) and potential launch byyear -end 2020, the market for EYSUVIS,

including the potential for EYSUVIS to be suitable for the vast majority of patients with dry eye disease, the Company’s plan toexpand its commercial sales force and the

Company’s expectations regarding its use of cash, cash runway and projected revenues. All statements, other than statements o f historical facts, contained in this presentation,

including statements regarding the Company’s strategy, future operations, future financial position, future revenue, projecte d costs, prospects, plans and objectives of

management, are forward -looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “inten d,” “may,” “plan,” “potential,” “predict,”

“project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward -looking statements, alt hough not all forward -looking statements contain

these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward -looking statements, and you should not place undue

reliance on such forward -looking statements. Actual results or events could differ materially from the plans, intentions and exp ectations disclosed in the forward -looking